Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

To evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of child patients who are predicted to have a high risk for developing severe acute graftversus-host disease (aGVHD) by the dynamic aGVHD Onset Anticipation Tianjin (daGOAT) model.

Inclusion Criteria:Patients must be ≤ 16 years of age;Patients receiving human leukocyte antigen mismatched and non-cord blood allogeneic hematopoietic stem cell transplantation;Patients who can take oral medication;Patients or their guardians have to sign an informed consent form before the start of the research procedure.Exclusion Criteria:Tandem transplantation or multiple transplantations;Patients who are allergic to or cannot tolerate ruxolitinib;Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements;Patients who are pregnant or cannot take appropriate contraceptive measures during treatment;Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.